deferasirox has been researched along with Symptom Cluster in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badawy, SM; Shah, A; Shah, R | 1 |
| Marsella, M; Ricchi, P | 1 |
| Kontoghiorghe, CN; Kontoghiorghes, GJ | 1 |
| Kohgo, Y; Kojima, S; Matsumura, I; Miyazaki, Y; Nakao, S; Niitsu, Y; Ohyashiki, K; Ozawa, K; Suzuki, T; Tomonaga, M | 1 |
| Berard, F; Martin, O; Nicolas, JF; Rozieres, A; Said, BB | 1 |
3 review(s) available for deferasirox and Symptom Cluster
| Article | Year |
|---|---|
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Biomarkers; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Syndrome; Thalassemia; Treatment Outcome; Triazoles | 2015 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles | 2016 |
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
Topics: Asian People; Benzoates; Bone Marrow Diseases; Data Collection; Deferasirox; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Japan; Practice Guidelines as Topic; Syndrome; Triazoles | 2008 |
2 other study(ies) available for deferasirox and Symptom Cluster
| Article | Year |
|---|---|
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia | 2023 |
Severe hypocalcemia and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome under deferasirox therapy for myelodysplasic syndrome.
Topics: Aged; Benzoates; Deferasirox; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Female; Humans; Hypocalcemia; Iron Chelating Agents; Myelodysplastic Syndromes; Syndrome; Triazoles | 2012 |